LGND EBITDA Growth
Ligand Pharmaceuticals Inc · EBITDA Growth
LGND EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported696.51%period ending
LGND TTM EBITDA YoY % (40.22% → 696.51%)
Year-over-year change
High-resolution chart · PNG
LGND ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 696.5149% | |
| 282.1467% | |
| 380.9144% | |
| 3.0194% | |
| -150.9245% | |
| -177.073% | |
| -59.7807% | |
| -31.1083% | |
| -47.1603% | |
| -12.7228% | |
| -17.5187% | |
| 120.9943% | |
| 174.7807% | |
| 191.3147% | |
| 53.2766% | |
| -33.34% | |
| -11.7457% | |
| -26.7116% | |
| 78.8731% | |
| 112.8539% | |
| 62.1074% | |
| 3,013.2552% | |
| -94.8741% | |
| -94.5087% | |
| -95.266% | |
| -99.7249% | |
| 343.7112% | |
| 205.4322% | |
| 383.9617% | |
| 660.1426% | |
| 138.7406% | |
| 297.122% | |
| 225.0613% | |
| 156.7241% | |
| 49.233% | |
| 50.7301% | |
| 26.8336% | |
| 14.5105% | |
| 78.6821% | |
| 49.8244% | |
| 86.2583% | |
| 105.4908% | |
| 32.5488% | |
| 51.0459% | |
| 27.3553% | |
| 8.4914% | |
| 25.3312% | |
| 18.7995% | |
| 60.5533% | |
| 160.9823% | |
| 549.6516% | |
| 234.8071% | |
| 448.7273% | |
| 120.4736% | |
| 117.5891% | |
| 149.0585% | |
| 109.8131% | |
| 113.9868% | |
| 104.9648% | |
| 52.7375% | |
| -470.6032% | |
| -417.3214% | |
| -267.5059% | |
| 72.6608% | |
| 95.4207% | |
| 94.547% | |
| 92.2434% | |
| -156.0891% | |
| -155.8491% | |
| -112.3591% | |
| -61.9145% | |
| 27.5343% | |
| 35.828% | |
| 20.9071% | |
| -70.7353% | |
| -13.7188% | |
| -178.6202% | |
| -634.5375% | |
| -281.4551% | |
| 0.0537% | |
| 61.809% | |
| 88.6727% | |
| 86.7627% | |
| -31.7276% | |
| -131.8744% | |
| -459.0529% | |
| -1,263.4062% | |
| -21.0601% | |
| 10.5914% | |
| 56.6506% | |
| 72.3365% | |
| -58.6648% | |
| -88.8473% | |
| -144.0667% | |
| -6.8703% | |
| 51.9282% | |
| 67.1494% | |
| 74.6617% | |
| 60.9035% | |
| 27.1771% |